drugset
drugset / Trial / NCT00651664

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

NCT00651664 ↗

Phase 1 Completed 59 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).

Timeline

Start
2007-10-22
Primary completion
2010-09-01
Completion
2011-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule 5 mg Oral
Subject Alisertib Small molecule 50 mg Oral
Subject Alisertib Small molecule 60 mg Oral
Subject Alisertib Small molecule 70 mg Oral
Subject Alisertib Small molecule 75 mg Oral
Subject Alisertib Small molecule 80 mg Oral
Subject Alisertib Small molecule 100 mg Oral
Subject Alisertib Small molecule 150 mg Oral

Indications

cancer